quinazolines has been researched along with plerixafor in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CP; Chao, YS; Chen, CT; Chou, MC; Hsieh, CJ; Jan, JJ; Kao, TT; Shia, KS; Song, JS; Tseng, CT; Wong, YC; Wu, CH; Wu, SH; Wu, SY; Yeh, CF; Yeh, KC | 1 |
| Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Wang, CC; Yang, YC | 1 |
| Foltz, G; Harrison, JK; Hothi, P; Law, BK; Luo, D; Pham, K; Reynolds, BA; Siemann, DW | 1 |
| Bae, E; Chen, CT; Kuan, HH; Shia, KS; Song, JS; Wang, Y; Wu, CH; Wu, KJ; Yeh, KC; Yu, SJ | 1 |
4 other study(ies) available for quinazolines and plerixafor
| Article | Year |
|---|---|
Discovery of novel stem cell mobilizers that target the CXCR4 receptor.
Topics: Animals; Benzylamines; Cyclams; Drug Evaluation, Preclinical; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Injections, Subcutaneous; Male; Mice; Mice, Inbred C57BL; Polyamines; Pyrimidines; Quinazolines; Receptors, CXCR4; Regenerative Medicine | 2012 |
Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzimidazoles; Benzylamines; Bone Marrow Cells; Chemokine CXCL12; Combined Modality Therapy; Cyclams; Dose Fractionation, Radiation; ErbB Receptors; Gefitinib; Green Fluorescent Proteins; Heterocyclic Compounds; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Prostatic Neoplasms; Quinazolines; Receptors, CXCR4; Tumor Microenvironment | 2013 |
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Benzylamines; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cyclams; Female; Glioblastoma; Heterocyclic Compounds; Humans; Interleukin-2 Receptor alpha Subunit; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, CXCR4; Receptors, Transforming Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Benzylamines; Brain; Brain Infarction; Chemotaxis; Cyclams; HEK293 Cells; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Interleukin-6; Male; Mice, Inbred C57BL; Neurons; Neuroprotection; Neuroprotective Agents; Quinazolines; Rats, Sprague-Dawley; Receptors, CXCR4; Stroke; Triazoles; Tumor Necrosis Factor-alpha | 2017 |